Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cell therapy for Inclusion Body Myositis by intramuscular autologous ADSVF
2024-511858-44-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived stromal vascular fraction in inclusion body myositis (IBM), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Oct 2024; status: authorised.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2024-511858-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511858-44-00.